Thermo Fisher Scientific’s PPD clinical research business struck a strategic partnership with Datavant to enable privacy‑preserving linkage of de‑identified patient data across more than 350 RWD partners and 80,000 U.S. hospitals and clinics. The collaboration will layer Datavant’s tokenization technology into Thermo Fisher’s RWD infrastructure to support trial enrichment and evidence generation. The connection aims to let sponsors enrich randomized trials with longitudinal electronic medical record data, improve study design, and accelerate recruitment through better real‑world cohort identification. Thermo Fisher framed the deal as a step toward scalable, privacy‑protected data interoperability for pharmaceutical and biotech customers. The alliance underscores growing demand from sponsors for integrated RWD and trial platforms to reduce development timelines and strengthen post‑market evidence generation.